Analyst Price Targets — BLCO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 6, 2026 12:40 pm | — | Evercore ISI | $17.00 | $17.06 | TheFly | Bausch + Lomb price target raised to $17 from $16 at Evercore ISI |
| April 30, 2026 1:05 pm | — | Deutsche Bank | $16.00 | $15.55 | TheFly | Bausch + Lomb price target lowered to $16 from $18 at Deutsche Bank |
| February 23, 2026 1:27 pm | — | H.C. Wainwright | $20.00 | $17.64 | TheFly | Bausch + Lomb price target raised to $20 from $17 at H.C. Wainwright |
| February 19, 2026 12:24 pm | — | Stifel Nicolaus | $16.00 | $17.67 | TheFly | Bausch + Lomb price target raised to $16 from $15 at Stifel |
| February 19, 2026 12:23 pm | — | Deutsche Bank | $18.00 | $17.67 | TheFly | Bausch + Lomb price target raised to $18 from $15 at Deutsche Bank |
| February 19, 2026 11:29 am | — | Barclays | $20.00 | $17.67 | TheFly | Bausch + Lomb price target raised to $20 from $17 at Barclays |
| February 17, 2026 1:04 pm | — | Stifel Nicolaus | $15.00 | $17.25 | TheFly | Bausch + Lomb price target raised to $15 from $14 at Stifel |
| January 27, 2026 12:53 pm | — | RBC Capital | $21.00 | $16.87 | TheFly | Bausch + Lomb price target raised to $21 from $19 at RBC Capital |
| January 9, 2026 10:49 am | David Roman | Goldman Sachs | $19.00 | $17.30 | TheFly | Bausch + Lomb price target raised to $19 from $17 at Goldman Sachs |
| January 5, 2026 11:20 am | Vijay Kumar | Evercore ISI | $18.00 | $16.58 | TheFly | Bausch + Lomb downgraded to In Line from Outperform at Evercore ISI |
Latest News for BLCO
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of the EyeGility™ Inserter preloaded IOL delivery system. “The enVista IOL platform has long been appreciated by surgeons for its glistening-free optic and differentiated optic portfolio to suit a wide range of…
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating BL1107 in patients with glaucoma. The study did not achieve its primary endpoint of replicating visual function improvements observed in a smaller Phase 1/2a study following 28 days…
VAUGHAN, Ontario, & MENLO PARK, Calif.--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the creation of Orphia™, a new AI-powered digital health platform built on the belief that eye care providers should spend less time managing disconnected tools and technologies and more time caring for…
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter financial results on Wednesday, July 29, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the…
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced new findings from its third annual State of Dry Eye survey, which reveals that the impact of dry eye can extend beyond the burden of physical symptoms, affecting how patients view their emotional health and wellbeing. This year's…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BLCO.
U.S. House Trading
No House trades found for BLCO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.